These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10586393)

  • 1. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation.
    Corey AE; Agnew JR; Valentine SN; Nesbitt JD; Wagner DL; Powell JH; Thompson GA
    J Clin Pharmacol; 1999 Dec; 39(12):1272-6. PubMed ID: 10586393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration.
    Corey AE; Agnew JR; Valentine SN; Parekh NJ; Powell JH; Thompson GA
    Br J Clin Pharmacol; 2002 Nov; 54(5):449-52. PubMed ID: 12445022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azimilide.
    Clemett D; Markham A
    Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
    Abrol R; Page RL
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
    Tran HT
    Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide.
    Phillips L; Grasela TH; Agnew JR; Ludwig EA; Thompson GA
    Clin Pharmacol Ther; 2001 Oct; 70(4):370-83. PubMed ID: 11673753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative oral bioavailability of azimilide dihydrochloride in the fed and fasted states.
    Corey AE; Agnew JR; Valentine SN; Nesbitt JD; Wagner DL; Powell JH; Thompson GA
    Br J Clin Pharmacol; 2000 Mar; 49(3):279-82. PubMed ID: 10718785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride.
    Corey A; Agnew J; Bao J; Bryson P; Comer P; Griffith S; Li J
    J Clin Pharmacol; 1997 Oct; 37(10):946-53. PubMed ID: 9505986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of azimilide on CYP2C19-mediated metabolism.
    El Mouelhi M; Worley DJ; Kuzmak B; Destefano AJ; Thompson GA
    J Clin Pharmacol; 2004 Apr; 44(4):373-8. PubMed ID: 15051744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R; Marcello S; Brooks RR; Corey AE; Moore A
    Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects.
    El Mouelhi M; Worley DJ; Kuzmak B; Destefano AJ; Thompson GA
    Br J Clin Pharmacol; 2004 Dec; 58(6):641-7. PubMed ID: 15563362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing.
    Corey A; Al-Khalidi H; Brezovic C; Marcello S; Parekh N; Taylor K; Karam R
    Biopharm Drug Dispos; 1999 Mar; 20(2):59-68. PubMed ID: 10206320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
    Page RL; Connolly SJ; Wilkinson WE; Marcello SR; Schnell DJ; Pritchett EL;
    Am Heart J; 2002 Apr; 143(4):643-9. PubMed ID: 11923801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride.
    Corey A; Agnew J; Brum J; Parekh N; Valentine S; Williams M
    J Clin Pharmacol; 1999 Dec; 39(12):1263-71. PubMed ID: 10586392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL; Marcello SR
    Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
    Pritchett EL; Page RL; Connolly SJ; Marcello SR; Schnell DJ; Wilkinson WE
    J Am Coll Cardiol; 2000 Sep; 36(3):794-802. PubMed ID: 10987602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration.
    Corey AE; Agnew JR; King EC; Parekh NJ; Powell JH; Thompson GA
    J Pharm Sci; 2004 May; 93(5):1279-86. PubMed ID: 15067704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation.
    Connolly SJ; Schnell DJ; Page RL; Wilkinson WE; Marcello SR; Pritchett EL
    Am J Cardiol; 2001 Nov; 88(9):974-9. PubMed ID: 11703992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of isoproterenol on the class III effect of azimilide in humans.
    Dorian P; Dunnmon P; Elstun L; Newman D
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.